The chemical class identified as UBTD1 Inhibitors encompasses a range of compounds designed to modulate the activity of UBTD1, a protein involved in the ubiquitin system. The primary action of these inhibitors is to interfere with the pathways and processes associated with UBTD1, particularly in the realm of protein degradation and ubiquitination. The inhibition of UBTD1's activity or its participation in ubiquitin-related functions can be achieved through various mechanisms. These include direct interference with the protein's ability to participate in the ubiquitin system, either by inhibiting its potential enzymatic activities or by disrupting its interactions with other proteins in the pathway. This type of inhibition is crucial because it can directly impact the protein's role in regulating ubiquitin-mediated processes, such as protein turnover, cell signaling, and the response to cellular stress.
In addition to directly targeting the mechanisms of UBTD1's activity, this class of inhibitors also includes compounds that modulate broader cellular processes and pathways associated with the ubiquitin system. By affecting these pathways, the inhibitors can create a cellular context that diminishes the functional demand or alters the activity of UBTD1. This approach takes into account the complex interplay between various components of the ubiquitin system and the multifaceted role that proteins like UBTD1 play in this system. It highlights the interconnectedness of cellular processes and the importance of understanding the broader implications of inhibiting a single component within a complex network. Furthermore, these inhibitors underscore the potential for indirect modulation of protein function, offering an avenue for influencing cellular mechanisms in which the direct targets and roles of proteins like UBTD1 are not fully elucidated. The development of UBTD1 inhibitors, therefore, represents a sophisticated approach to understanding and influencing the mechanisms of the ubiquitin system at the cellular level. These inhibitors serve as valuable tools for probing the function of UBTD1 and offer insights into the complex mechanisms of protein regulation. By targeting both the direct activities of UBTD1 and the broader network of interactions and pathways in which it operates, UBTD1 inhibitors embody the intricate strategies required for effective modulation of key components within cellular regulatory systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Could potentially inhibit UBTD1 by disrupting the ubiquitin-proteasome pathway, affecting protein degradation processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Could potentially inhibit UBTD1 by targeting the proteasome, indirectly influencing ubiquitin-related functions. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Could potentially inhibit UBTD1 by inhibiting proteasome activity, impacting ubiquitin-mediated protein degradation. | ||||||
ATM/ATR Kinase Inhibitor Inhibitor | 905973-89-9 | sc-202964 | 5 mg | $106.00 | 8 | |
Could potentially inhibit UBTD1 by inhibiting NEDD8-activating enzyme, affecting ubiquitin-like protein conjugation pathways. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Could potentially inhibit UBTD1 by inhibiting ubiquitin-activating enzyme E1, impacting ubiquitination processes. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
Could potentially inhibit UBTD1 by broadly inhibiting deubiquitinating enzymes, impacting ubiquitin-dependent signaling. | ||||||
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
Could potentially inhibit UBTD1 by disrupting DUB activity, indirectly influencing ubiquitin-mediated protein turnover. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Could potentially inhibit UBTD1 by modulating ubiquitin ligase activity, affecting protein degradation pathways. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Could potentially inhibit UBTD1 by modulating p53 and MDM2 interaction, indirectly affecting ubiquitin-mediated processes. | ||||||